{"protocolSection": {"identificationModule": {"nctId": "NCT00832455", "orgStudyIdInfo": {"id": "0476-385"}, "secondaryIdInfos": [{"id": "MK0476-385"}, {"id": "2009_523"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)", "officialTitle": "A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair\u00ae), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06"}, "primaryCompletionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-01-28", "studyFirstSubmitQcDate": "2009-01-28", "studyFirstPostDateStruct": {"date": "2009-01-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-25", "resultsFirstSubmitQcDate": "2010-01-18", "resultsFirstPostDateStruct": {"date": "2010-02-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids"}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 445, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Montelukast", "type": "EXPERIMENTAL", "interventionNames": ["Drug: montelukast sodium"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "Montelukast 4-5 mg for 12 weeks, oral tablet", "armGroupLabels": ["Montelukast"], "otherNames": ["Singular"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control Questionnaire (ACQ)", "description": "ACQ is a questionnaire consisting of seven 7-point Likert scale questions describing frequency and severity of asthma symptoms. Score ranges between 0 (well-controlled) and 6 (extremely poorly controlled); a score of \u22640.75 indicates well controlled symptoms.", "timeFrame": "Week 0, 4, and 12"}], "secondaryOutcomes": [{"measure": "Asthma Control Questionnaire (ACQ)", "description": "ACQ is a questionnaire consisting of seven 7-point Likert scale questions describing frequency and severity of asthma symptoms. Score ranges between 0 (well-controlled) and 6 (extremely poorly controlled); a score of \u22640.75 indicates well controlled symptoms.", "timeFrame": "Week 0, 4, and 12"}], "otherOutcomes": [{"measure": "Physician Global Satisfaction", "description": "At week 0, 4, 8 and 12, physicians were asked to complete a single question describing how satisfied they were regarding the asthma controller medication for each of their enrolled patients.", "timeFrame": "week 0, 4, 8 and 12"}, {"measure": "Patient Global Satisfaction", "description": "At week 0, 4, 8 and 12, patients were asked to complete a single question describing how satisfied they were regarding their asthma controller medication.", "timeFrame": "Week 0, 4, 8 and 12"}, {"measure": "Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)", "description": "The change in the quality of life of the caregivers of patients treated with montelukast for the control of asthma used in combination with inhaled corticosteroids, using the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ).\n\nPACQLQ score ranges between 1 (severe impairment) and 7 (no impairment) where a higher score indicates better quality of life. An average change in overall score \u22650.7 is considered clinically significant. Changes between visits and baseline are described.", "timeFrame": "Weeks 4, 8, and 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient Is Diagnosed With Asthma For At Least 6 Months\n* Patient's Peak Expiratory Flow (PEF) Is 80% Of Predicted Value (Appendix 10)\n* Patient Is Currently Untreated, Or Patient Is A User Of Short-Acting 2-Agonist On An As-Needed Basis, Or Patient Is A User Of Ics At Any Dosage\n* Physician And/Or Patient Are Dissatisfied With Current Controller Therapy, Or Patient Is Reluctant To Take Ics Therapy, Or Patient Is Insufficiently Controlled Due To Non-Adherence With Current Therapy Through The Preceding 6 Weeks\n\nExclusion Criteria:\n\n* As Per Canadian Guidelines, Patient Is On A Laba Alone (Formoterol (Oxeze), Salmeterol (Serevent)) Or A Combination Product (Advair Or Symbicort)\n* Patient Is Well Controlled, Adherent And Satisfied With Current Controller Therapy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "2 Years", "maximumAge": "14 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "24932181", "type": "RESULT", "citation": "Berube D, Djandji M, Sampalis JS, Becker A. Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study. Allergy Asthma Clin Immunol. 2014 May 6;10(1):21. doi: 10.1186/1710-1492-10-21. eCollection 2014."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "First patient in: JUN-19-2006\n\nLast patient out: OCT-28-2008\n\nTotal number of sites: 37 sites in Canada", "groups": [{"id": "FG000", "title": "Montelukast", "description": "Montelukast 4-5 mg for 12 weeks, oral tablet"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "445 - number of patients that signed the informed consent form (Safety population)", "numSubjects": "445"}]}, {"type": "Baseline", "achievements": [{"groupId": "FG000", "comment": "420 -patients that received at least one dose of study medication and had 1 follow-up visit (ITT)", "numSubjects": "420"}]}, {"type": "Week 4", "achievements": [{"groupId": "FG000", "numSubjects": "411"}]}, {"type": "Week 8 (Optional)", "achievements": [{"groupId": "FG000", "numSubjects": "247"}]}, {"type": "Week 12", "achievements": [{"groupId": "FG000", "numSubjects": "373"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "373"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "72"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "13"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "26"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "17"}]}, {"type": "Screening Failure", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Stopped Medication", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Parent misunderstood study", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Parent dissatisfied", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "No improvement", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Patient moved", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast", "description": "Montelukast 4-5 mg for 12 weeks, oral tablet"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "420"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.00", "spread": "3.33"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "168"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "252"}]}]}]}, {"title": "ICS (Inhaled Corticosteroids) Use", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Use", "categories": [{"measurements": [{"groupId": "BG000", "value": "323"}]}]}, {"title": "No Use", "categories": [{"measurements": [{"groupId": "BG000", "value": "97"}]}]}]}, {"title": "Asthma Diagnosis Duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.58", "spread": "34.72"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control Questionnaire (ACQ)", "description": "ACQ is a questionnaire consisting of seven 7-point Likert scale questions describing frequency and severity of asthma symptoms. Score ranges between 0 (well-controlled) and 6 (extremely poorly controlled); a score of \u22640.75 indicates well controlled symptoms.", "populationDescription": "420 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 411 patients who completed week 4 and the 373 patients who completed week 12.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 0, 4, and 12", "groups": [{"id": "OG000", "title": "Montelukast ITT at Week 0", "description": "ITT population, receiving montelukast 4 or 5 mg/day"}, {"id": "OG001", "title": "Montelukast ITT at Week 4", "description": "ITT population, receiving montelukast 4 or 5 mg/day"}, {"id": "OG002", "title": "Montelukast ITT at Week 12", "description": "ITT population, receiving montelukast 4 or 5 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "420"}, {"groupId": "OG001", "value": "411"}, {"groupId": "OG002", "value": "373"}]}], "classes": [{"title": "Not well controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "328"}, {"groupId": "OG001", "value": "159"}, {"groupId": "OG002", "value": "96"}]}]}, {"title": "Well controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "251"}, {"groupId": "OG002", "value": "276"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ)", "description": "ACQ is a questionnaire consisting of seven 7-point Likert scale questions describing frequency and severity of asthma symptoms. Score ranges between 0 (well-controlled) and 6 (extremely poorly controlled); a score of \u22640.75 indicates well controlled symptoms.", "populationDescription": "420 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 411 patients who completed week 4, the 247 who completed week 8, and the 373 patients who completed week 12.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 0, 4, and 12", "groups": [{"id": "OG000", "title": "Montelukast ITT at Week 0", "description": "ITT population, receiving montelukast 4 or 5 mg/day"}, {"id": "OG001", "title": "Montelukast ITT at Week 4", "description": "ITT population, receiving montelukast 4 or 5 mg/day"}, {"id": "OG002", "title": "Montelukast ITT at Week 12", "description": "ITT population, receiving montelukast 4 or 5 mg/day"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "420"}, {"groupId": "OG001", "value": "411"}, {"groupId": "OG002", "value": "373"}]}], "classes": [{"title": "Not tapered and Not well controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "82"}]}]}, {"title": "Not tapered and Well controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "216"}]}]}, {"title": "Tapered and Not well controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "Tapered and Well controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "60"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Physician Global Satisfaction", "description": "At week 0, 4, 8 and 12, physicians were asked to complete a single question describing how satisfied they were regarding the asthma controller medication for each of their enrolled patients.", "populationDescription": "420 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 411 patients who completed week 4, the 247 who completed week 8, and the 373 patients who completed week 12.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "week 0, 4, 8 and 12", "groups": [{"id": "OG000", "title": "Montelukast ITT at Week 0"}, {"id": "OG001", "title": "Montelukast ITT at Week 4"}, {"id": "OG002", "title": "Montelukast ITT at Week 8"}, {"id": "OG003", "title": "Montelukast ITT at Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "420"}, {"groupId": "OG001", "value": "411"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "373"}]}], "classes": [{"title": "Very satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "130"}, {"groupId": "OG002", "value": "116"}, {"groupId": "OG003", "value": "186"}]}]}, {"title": "Satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "100"}, {"groupId": "OG003", "value": "136"}]}]}, {"title": "Neither Satisfied or Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "22"}, {"groupId": "OG003", "value": "32"}]}]}, {"title": "Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "14"}]}]}, {"title": "Very Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "3"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar-Bowker", "statisticalComment": "The McNemar-Bowker test is a statistical procedure used to compare the proportion of physician satisfaction at week 0 compared to week 12.", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar-Bowker", "statisticalComment": "The McNemar-Bowker test is a statistical procedure used to compare the proportion of physician satisfaction at week 0 compared to week 8.", "ciPctValue": "95"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Patient Global Satisfaction", "description": "At week 0, 4, 8 and 12, patients were asked to complete a single question describing how satisfied they were regarding their asthma controller medication.", "populationDescription": "420 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 411 patients who completed week 4, the 247 who completed week 8, and the 373 patients who completed week 12.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 0, 4, 8 and 12", "groups": [{"id": "OG000", "title": "Montelukast ITT at Week 0"}, {"id": "OG001", "title": "Montelukast ITT at Week 4"}, {"id": "OG002", "title": "Montelukast ITT at Week 8"}, {"id": "OG003", "title": "Montelukast ITT at Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "420"}, {"groupId": "OG001", "value": "411"}, {"groupId": "OG002", "value": "247"}, {"groupId": "OG003", "value": "373"}]}], "classes": [{"title": "Very Satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "129"}, {"groupId": "OG003", "value": "194"}]}]}, {"title": "Satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "161"}, {"groupId": "OG002", "value": "87"}, {"groupId": "OG003", "value": "120"}]}]}, {"title": "Neither Satisfied or Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "48"}]}]}, {"title": "Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "7"}]}]}, {"title": "Very Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar-Bowker", "statisticalComment": "The McNemar-Bowker test is a statistical procedure used to compare the proportion of patient satisfaction at week 0 compared to week 12.", "ciPctValue": "95"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)", "description": "The change in the quality of life of the caregivers of patients treated with montelukast for the control of asthma used in combination with inhaled corticosteroids, using the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ).\n\nPACQLQ score ranges between 1 (severe impairment) and 7 (no impairment) where a higher score indicates better quality of life. An average change in overall score \u22650.7 is considered clinically significant. Changes between visits and baseline are described.", "populationDescription": "420 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 411 patients who completed week 4, the 247 who completed week 8, and the 373 patients who completed week 12.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a Scale", "timeFrame": "Weeks 4, 8, and 12", "groups": [{"id": "OG000", "title": "Montelukast ITT at Week 4"}, {"id": "OG001", "title": "Montelukast ITT at Week 8"}, {"id": "OG002", "title": "Montelukast ITT at Week 12"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "247"}, {"groupId": "OG002", "value": "373"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.06", "spread": "1.27"}, {"groupId": "OG001", "value": "1.39", "spread": "1.39"}, {"groupId": "OG002", "value": "1.36", "spread": "1.34"}]}]}], "analyses": [{"groupIds": ["OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "Change in PACQLQ score between Week 12 and baseline is statistically different than zero", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "eventGroups": [{"id": "EG000", "title": "Montelukast", "description": "Montelukast 4-5 mg for 12 weeks, oral tablet", "seriousNumAffected": 5, "otherNumAffected": 146}], "seriousEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 445}]}, {"term": "Pneumomia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 445}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 445}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 445}]}], "otherEvents": [{"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 445}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 445}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 31, "numAffected": 30, "numAtRisk": 445}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 445}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 445}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 445}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 33, "numAtRisk": 445}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 15, "numAtRisk": 445}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 445}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 445}]}, {"term": "Nightmare", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 445}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 26, "numAffected": 26, "numAtRisk": 445}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 445}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 445}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 445}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}